On September 22, under the guidance of the National Biopharmaceutical Enterprise Platform, the "2025 China Biopharmaceutical Technology Innovation Value List" initiated by Yiyun Technology and the National Technology Transfer Eastern Center has been officially announced. Novamab once again topped the TOP10 list of the most promising biopharmaceutical enterprises.

The TOP10 list of the Most Promising Biopharma companies focuses on innovative enterprises that continuously explore and break through in segmented technology and target areas. These enterprises represent the key reserve forces for China's biopharmaceutical innovation vitality and international competitiveness, nurturing future stars in the industry. Novamab has been listed in the TOP10 list for two consecutive years due to its outstanding innovative achievements in the research and development of VHH innovative drugs. This is not only a high affirmation of its past technological accumulation and market performance, but also fully reflects the industry's high recognition of its strong growth potential and future development.

Novamab has always maintained a keen insight and strong innovation ability, daring to break through in the exploration of segmented technologies and targets, focusing on the research and development of innovative VHH drugs, and committed to making breakthrough progress in the fields of respiration and self immunity. In the future, Novamab will maintain a steady pace, actively promote clinical and research and development projects, continue to deepen the research and development of VHH innovative drugs, and strive to become a leading global VHH innovative drug research and development enterprise in the respiratory and autoimmune fields. It is committed to providing safer, more effective, and more convenient therapeutic drugs for patients, while contributing key forces to the innovation vitality and international competitiveness of China's biopharmaceutical industry.

About Huayi List

The Huayi List · 2025 China Biomedical Technology Innovation Value List focuses on the structural transformation needs of China's biopharmaceutical industry during the transition period from the end of the 14th Five Year Plan to the 15th Five Year Plan, and is committed to discovering innovative enterprises with industry appeal and influence. This list is based on the quantitative growth evaluation criteria for enterprises, which have been refined by Huayi Research Institute over the years. It involves processes such as questionnaire surveys, enterprise interviews, data analysis, and verification. The evaluation team standardizes and quantitatively assesses the dynamic data of shortlisted enterprises and institutions, selecting those with significant industry value for the year to form an objective third-party evaluation list in the industry. Its core goal is to use scientific quantitative models to identify enterprises that truly possess clinical value and global competitiveness, serving as an authoritative guide for policy formulation and capital allocation.

About Novamab 

Novamab is located in the Shanghai International Medical Park (Pudong New District). It is an innovative biopharmaceutical company in the clinical stage, dedicated to developing VHH antibody drugs targeting the multi-billion-dollar markets of respiratory diseases and inflammatory disorders. Our mission is to enhance the efficacy and ease of use of innovative VHH drugs through research and development, and provide patients with treatment plans that change their quality of life. 

The company utilizes the advanced NanoVibe VHH platform to fully leverage the advantages of VHHs, creating highly differentiated antibody drug platforms, including the inhaled antibody platform (Aerobody), the oral antibody platform (Orabody), and the dual/multi-antibody platform (Pluribody). Our product pipeline includes the FIC Phase II clinical inhaled IL-4R VHH, the Phase I clinical inhaled TSLP VHH, and multiple TL1A dual/multi-antibodies and oral pipelines, targeting indications such as asthma, chronic obstructive pulmonary disease (COPD), and inflammatory bowel disease (IBD). 

The company has attracted the attention and support of several well-known investment institutions and funds, including Zhang Ke LINGYI, Qiming Venture Partners, and Shengdi Investment, among others. We currently have approximately 60 full-time employees so far.